Switzerland’s AC Immune, which already has money in hand from Roche for its most advanced drug, is planning a share sale in the United States to raise up to $50 million for separate drug candidates targeting Alzheimer’s disease.
The company, run by former Nestle global research head Andrea Pfeifer, joins other European biotech firms that have opted to list in New York to tap the deeper pool of capital available in the United States and the presence of more specialist investors.
British cancer immunotherapy firm Adaptimmune also opted for a Nasdaq listing last year, while cannabis drugmaker GW Pharmaceuticals and French allergy company DBV Technologies have both had successful U.S. offerings.
